Study treatment after liver surgery or microwave ablation for liver cancer
Part of Cancer, Digestive system clinical trials.
This study tests an investigational drug called IP-001 given after surgery or microwave ablation for liver cancer. The goal is to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- You are scheduled to have microwave ablation or surgery to remove the tumor.
- Your cancer is only in the liver, not spread to other parts of the body.
- You are in good enough health to carry out daily activities (ECOG score 0 or 1).
- You do not have an allergy to shellfish or to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study combines microwave ablation, which uses heat to destroy cancer cells, with immune cell therapy that boosts your body's natural defenses to fight the cancer. It may help people with early-stage liver cancer who cannot have surgery.
This trial compares two ways to treat hepatocellular carcinoma (a type of liver cancer): microwave ablation and laparoscopic hepatectomy (keyhole liver surgery). It may help find which option works better for tumor control and recovery in people with limited, non-spread cancer.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests a combination of focused radiation (SBRT), an immunotherapy drug (adelimumab), and a targeted therapy pill (apatinib) for liver cancer that can be removed with surgery. The goal is to see if this combination can shrink tumors before surgery and help prevent the cancer from coming back.
This trial tests whether adding the drug IP-001 to tumor ablation (microwave or irreversible electroporation) helps control colorectal cancer that has spread to the liver. The goal is to find the best dose and see how the immune system responds.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.